Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…